Fair Value Calculator Fair Value Calculator
EN DE

GILADAFINS (GILADAFINS) Fair Value & Analysis

IN · Market cap ₹194M

G GILADAFINS GILADAFINS · BSE
Price₹13.84
Fair Value₹19.42
Upside+40.3%
Quality51/100
Watch GILADAFINS for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹19.42 – ₹25.25

Fair value as of: Jul 5, 2026

From 24 valuation models · updated today

Share price +17.1% over the past month.

Price vs Fair Value (12 months)

₹21.76 ₹11.38 Fair Value ₹19.42 Jul 2025 Jul 2026

12‑month range ₹11.38 – ₹21.76 · fair‑value band ₹19.42 – ₹25.25 · the ₹13.84 price screens below the ₹19.42 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

GILADAFINS (GILADAFINS) currently trades at ₹13.84, while our model-based Fair Value estimate is ₹19.42 — implying the stock looks roughly 40.3% undervalued today. We read business quality at 51/100 (solid quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Net debt stands at ₹104M. The stock trades on a trailing P/E of 8.9. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹19.42 (bear case) to ₹25.25 (bull case); at ₹13.84, the current price sits below that range. The share trades about 42% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Free cash flow ₹5.4M FY2026
P/E ratio 8.9
EPS (TTM) ₹1.55
Net debt ₹104M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

GILADAFINS reported revenue of ₹72.6M in FY2026 versus ₹37.5M in FY2022, a compound +17.9%/yr. Reported net income was ₹21.7M in FY2026, compounding +13.1%/yr from FY2022.

Revenue +17.9%/yr
FY22 ₹37.5M
FY23 ₹43.3M
FY24 ₹62.3M
FY25 ₹67.7M
FY26 ₹72.6M
Net income +13.1%/yr
FY22 ₹13.3M
FY23 ₹15.2M
FY24 ₹17.0M
FY25 ₹21.3M
FY26 ₹21.7M

Is GILADAFINS fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "GILADAFINS Fair Value". https://www.fairvalue-calculator.com/stock/GILADAFINS

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is GILADAFINS (GILADAFINS) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹19.42 versus a price of ₹13.84 — about +40% (undervalued). Model-based estimate, not financial advice.
What is the fair value of GILADAFINS?
Our model-based fair value for GILADAFINS is ₹19.42 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹13.84.
What is the quality score of GILADAFINS?
GILADAFINS has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of GILADAFINS?
The net profit margin of GILADAFINS is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.